Opus Genetics Inc (fra:R3X1) Share Price

Company Profile

Business description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Contact
8 Davis Drive
Suite 220
DurhamNC27709
USA
T: +1 984 884-6030
https://www.opusgtx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
18

Recommended

Finding companies built for lasting dividend growth.

Jen Nurick | 02 December 2025

Global spending spree on data centres could mean a declining return on invested capital.

Yingqi Tan, CFA | 02 December 2025

After a takeover bid was withdrawn shares dropped to below the pre-bid price.

Nathan Zaia | 01 December 2025

Index	Last price	Change	% Change
All Ordinaries	8,894.20	5.90	0.07%
CAC 40	8,074.61	22.39	-0.28%
DAX 40	23,710.86	121.42	0.51%
Dow JONES (US)	47,474.46	185.13	0.39%
FTSE 100	9,701.80	0.73	-0.01%
HKSE	25,769.79	325.26	-1.25%
NASDAQ	23,413.67	137.75	0.59%
Nikkei 225	49,864.68	561.23	1.14%
NZX 50 Index	13,582.54	79.77	0.59%
S&P 500	6,829.37	16.74	0.25%
S&P/ASX 200	8,595.20	4.90	0.06%
SSE Composite Index	3,878.00	19.71	-0.51%